0001127602-22-018097.txt : 20220624 0001127602-22-018097.hdr.sgml : 20220624 20220624123319 ACCESSION NUMBER: 0001127602-22-018097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220622 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kenny John P. CENTRAL INDEX KEY: 0001719325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14902 FILM NUMBER: 221038916 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC CENTRAL INDEX KEY: 0000794172 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 310888197 STATE OF INCORPORATION: OH FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 3471 RIVER HILLS DR CITY: CINCINNATI STATE: OH ZIP: 45244 BUSINESS PHONE: 5132713700 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 FORMER COMPANY: FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-06-22 0000794172 MERIDIAN BIOSCIENCE INC VIVO 0001719325 Kenny John P. 3471 RIVER HILLS DRIVE CINCINNATI OH 45244 1 1 Chief Executive Officer Common Stock 2022-06-22 4 M 0 44651 14.50 A 309782 D Common Stock 2022-06-22 4 S 0 44651 29.7176 D 265131 D Common Stock 2022-06-23 4 M 0 5349 14.50 A 270480 D Common Stock 2022-06-23 4 M 0 14607 10.10 A 285087 D Common Stock 2022-06-23 4 S 0 19956 29.9764 D 265131 D Stock Options (Right to Buy) 14.50 2022-06-22 4 M 0 44651 0 D 2027-10-09 Common Stock 44651 5349 D Stock Options (Right to Buy) 14.50 2022-06-23 4 M 0 5349 0 D 2027-10-09 Common Stock 5349 0 D Stock Options (Right to Buy) 10.10 2022-06-23 4 M 0 14607 0 D 2029-11-05 Common Stock 14607 141035 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $29.94. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.61 to $30.13. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. These non-qualified options were awarded under the 2012 Stock Incentive Plan upon Mr. Kenny being hired as Chief Executive Officer. The options vested in four (4) equal installments from the date of grant until fully vested on October 9, 2021. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021. These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date. /s/ Jeffery T. Pinkston as Attorney-in-fact for John P. Kenny 2022-06-24